Blockade of VEGF/VEGFR signaling can improve anti-PD-1 or anti-PD-L1 antibodies’ antitumor activities in murine tumor models of colorectal, pancreatic, breast, and small cell lung cancer [24, 26–28]. The gene discussed is PDCD1; the disease is neoplasm.